List of Triumeq Pd drug patents

Triumeq Pd is owned by Viiv Hlthcare.

Triumeq Pd contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.

Triumeq Pd has a total of 2 drug patents out of which 0 drug patents have expired.

Triumeq Pd was authorised for market use on 30 March, 2022.

Triumeq Pd is available in tablet, for suspension;oral dosage forms.

The generics of Triumeq Pd are possible to be released after 08 December, 2029.

TRIUMEQ PD's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 30 March, 2022

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

TRIUMEQ PD family patents

33

United States

15

Japan

13

European Union

9

Spain

7

Korea, Republic of

6

Hungary

6

Slovenia

6

Denmark

5

Portugal

5

Norway

5

Mexico

5

Hong Kong

5

Poland

4

Lithuania

4

Canada

4

Australia

3

Brazil

3

China

3

Taiwan, Province of China

3

Cyprus

3

Israel

2

Russia

2

Morocco

2

EA

2

South Africa

2

Luxembourg

2

Netherlands

1

Singapore

1

New Zealand

1

Philippines

1

Austria

1

Ukraine

1

Viet Nam

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in